In-Patient Hospitalization vs. At-Home Programs: Will Doctors Be Making House Calls Again?

Ash Clinical News recently interviewed Dr. Bruce Leff of Johns Hopkins in connection with “hospital-at-home”, one of the major changes occurring in hospital care. Dr. Leff and his team at…

Continue Reading In-Patient Hospitalization vs. At-Home Programs: Will Doctors Be Making House Calls Again?

New Drug Under Review by the FDA to Treat the Most Lethal Form of Spinal Muscular Atrophy

  According to an article in Biospace, the FDA is currently reviewing data from the Phase III STRIVE clinical trial for possible approval of Zolgensma as gene therapy for spinal…

Continue Reading New Drug Under Review by the FDA to Treat the Most Lethal Form of Spinal Muscular Atrophy

Fulcrum Therapeutics Acquires Experimental Facioscapulohumeral Muscular Dystrophy Drug

According to a press release from Massachusetts-based biotech company Fulcrum Therapeutics, the company has successfully secured global commercialization rights of GlaxoSmithKline-developed experimental facioscapulohumeral muscular dystrophy (FSHD) drug losmapimod. Losmapimod, an…

Continue Reading Fulcrum Therapeutics Acquires Experimental Facioscapulohumeral Muscular Dystrophy Drug
Inflammatory Bowel Disease Patient Wellness Chatbot Starts 6-Week Test Run
https://pixabay.com/en/technology-robot-human-hand-2025795/

Inflammatory Bowel Disease Patient Wellness Chatbot Starts 6-Week Test Run

According to an article from CW associate WBCB, Dutch startup Nori Health has started open enrollment in the six-week test of its eponymous experimental chatbot, Nori. Nori aims to help…

Continue Reading Inflammatory Bowel Disease Patient Wellness Chatbot Starts 6-Week Test Run
More Evidence Suggesting Nusinersen Effective for Spinal Muscular Atrophy Types II and III
kkolosov / Pixabay

More Evidence Suggesting Nusinersen Effective for Spinal Muscular Atrophy Types II and III

According to a press release from the American Academy of Neurology published by EurekAlert, new research published in Neurology further suggests that established spinal muscular atrophy (SMA) drug nusinersen could…

Continue Reading More Evidence Suggesting Nusinersen Effective for Spinal Muscular Atrophy Types II and III

Phase 2a Clinical Trial for Investigational Cell Therapy Now Recruiting Primary Sclerosing Cholangitis and Autoimmune Hepatitis Patients

Primary Sclerosing Cholangitis (PSC) and Autoimmune Hepatitis (AIH) are both rare and chronic liver diseases. They cause the bile ducts in the liver to become inflamed, resulting in severe liver damage.…

Continue Reading Phase 2a Clinical Trial for Investigational Cell Therapy Now Recruiting Primary Sclerosing Cholangitis and Autoimmune Hepatitis Patients

Orphan Drug Designation Given to New Potential Oral Therapy for Hypereosinophilic Syndrome

Hypereosinophilic Syndrome Hypereosinophilic syndrome (HES) is a rare disease which causes high levels of white blood cells in the body. These cells are called eosinophils, and they're essential for proper…

Continue Reading Orphan Drug Designation Given to New Potential Oral Therapy for Hypereosinophilic Syndrome